Please select an option below to help us tailor your newsletter to best suit your content interests!
Advancements in ROS1-Positive Non-Small Cell Lung Cancer A recent article from CURE Today highlights the progress being made in targeted therapies for this rare subtype of lung cancer, which affects around 1-2% of patients. Our West family is proud to be at the forefront of this critical work, where Dr. Jason Porter and his team… Read more »
Dr. Jason Porter details groundbreaking research for KRAS-mutant NSCLC during a Targeted Oncology Community Case Forum. 🎉 Explore the CodeBreaK 100 and CodeBreaK 200 studies, showing promising results and insights into new treatment strategies. Read more about the accelerated approval of new treatment options, and their impact on patients’ lives. Let’s revolutionize #LungCancer care together!… Read more »
Exciting News in Lung Cancer Treatment Dr. Jason Porter joins Dr. Maya Khalil, Dr. Brian Mitzman, and Dr. Rami Manochakian in discussing the strides made in improving patient outcomes with immunotherapy and targeted therapies for non-small cell lung cancer (NSCLC). The group talks about several new clinical trials demonstrating promising results for high… Read more »
Our very own Dr. Jason Porter was a recent guest on the Research Evangelist Podcast. This podcast hosts weekly discussions with leaders in the lung cancer research community. Host, David Bjork, is a lung cancer survivor himself and patient advocate. He and Dr. Porter discuss molecularly-altered lung cancers, as well as those lung cancers with… Read more »
Through research and partnerships across the oncology community, we are committed to closing the gap in existing disparities in cancer care. A new study in partnership with Dr. Gregory Vidal and our West family, OneOncology, Genentech, and Flatiron Health examined elements of inequity in next generation sequencing (NGS) for patients with advanced non-small cell lung… Read more »